I think Pfizer has them beat, but not by much. Looks better than the Astrazeneca data. (Fig 5, ref to Convalescent response which is also in Pfizer figure). thelancet.com/journals/lance…
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report...
ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses,...thelancet.com
12:56 PM · Jan 14, 2021